Nov 13, 2023
News
At NGM, we pride ourselves on conducting world-class science and sharing our research efforts with the broader scientific and medical communities.
Nov 07, 2023
NGM Bio to Participate in Upcoming Investor Conferences
Nov 02, 2023
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
Oct 11, 2023
NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®
Aug 03, 2023
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights
May 25, 2023
NGM Bio to Participate in Upcoming Investor Conferences
May 08, 2023
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023
May 04, 2023
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data
Mar 01, 2023
NGM Bio to Participate in the Cowen 43rd Annual Health Care Conference
Feb 28, 2023
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
Jan 12, 2023
NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
Jan 09, 2023